Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263710 | 0.80 | POLB (0.39) | TP53TSHRALDH1A1POLBMAPT | |
| SCHEMBL18640947 | 0.78 | POLB (0.57) | TP53TSHRGRM5KCNH2HTR6 | |
| SCHEMBL16468271 | 0.76 | POLB (0.50) | TP53POLBMAPT | |
| SCHEMBL12068158 | 0.72 | KMT2A (0.52) | TP53TSHRALDH1A1 | |
| SCHEMBL16491313 | 0.71 | TP53 (0.46) | TP53POLBMAPT | |
| SCHEMBL18640914 | 0.71 | JAK2 (0.30) | — | |
| SCHEMBL16612234 | 0.70 | TP53 (0.44) | TP53TSHRPOLBMAPT | |
| SCHEMBL26671291 | 0.69 | HTR3E (0.34) | GRM5 | |
| SCHEMBL31605738 | 0.67 | LPL (0.49) | — | |
| SCHEMBL6311907 | 0.67 | LPL (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | REN 708/4885TP53 1910/4885TSHR 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.